Pfizer has secured early US approval for its bid to acquire Metsera, an obesity biotech, potentially signaling government intervention in the public battle with Novo Nordisk. This development may impact the weight loss market, as Pfizer aims to expand its presence in the sector. The approval could also influence the dynamics between Pfizer and Novo Nordisk in their pursuit of Metsera.